Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Diseasekatie8288Jun 25, 20240 min read
Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and other select markets
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Comments